Can Bactrim and Lisinopril Be Given Together?
Use extreme caution when co-prescribing trimethoprim-sulfamethoxazole (Bactrim) with lisinopril (ACE inhibitor), and avoid this combination in high-risk patients—particularly those over 65 years, with any degree of renal impairment, or taking additional potassium-affecting medications—because the risk of life-threatening hyperkalemia is substantially elevated. 1, 2, 3
Risk Stratification and Decision Algorithm
High-Risk Patients (Avoid Combination)
- Age ≥65 years: The 2019 AGS Beers Criteria explicitly warns that trimethoprim-sulfamethoxazole should be used with caution in older adults taking ACE inhibitors or ARBs due to increased hyperkalemia risk 1
- Any renal impairment (even mild): Patients with creatinine >1.6 mg/dL or eGFR <60 mL/min face dramatically increased risk 2, 4, 5
- Baseline potassium >4.5 mEq/L: Even upper-normal potassium becomes dangerous with this combination 2, 3
- Concurrent potassium-sparing diuretics (spironolactone, amiloride, triamterene): This triple combination carries extreme risk, with one study showing adjusted odds ratio of 12.4 for hospitalization with hyperkalemia 6
- Diabetes with any nephropathy: These patients have impaired potassium homeostasis 3, 7
In these populations, select an alternative antibiotic (amoxicillin, cephalosporin, or fluoroquinolone if clinically appropriate). 3, 6
Lower-Risk Patients (May Use with Intensive Monitoring)
If the patient has all of the following, the combination may be considered:
- Age <65 years
- Normal renal function (eGFR >60 mL/min, creatinine <1.5 mg/dL)
- Baseline potassium <4.5 mEq/L
- No diabetes
- No concurrent potassium-sparing diuretics or potassium supplements
- No other medications impairing potassium excretion (NSAIDs, other RAAS inhibitors)
Even in this lower-risk group, mandatory monitoring is required. 1, 2
Mechanism of Hyperkalemia Risk
Trimethoprim blocks epithelial sodium channels (ENaC) in the distal nephron—the same mechanism as amiloride—thereby reducing renal potassium excretion 4, 5. When combined with an ACE inhibitor (which suppresses aldosterone and further impairs potassium excretion), the effects are additive and can produce severe, life-threatening hyperkalemia within days 3, 7.
This is not a theoretical risk: A population-based study of 4,148 elderly patients on ACE inhibitors or ARBs found that trimethoprim-sulfamethoxazole increased the risk of hyperkalemia-associated hospitalization nearly 7-fold (adjusted OR 6.7,95% CI 4.5-10.0) compared to amoxicillin 3. The median time to hospitalization was only 8-14 days after starting the antibiotic 3, 7.
Mandatory Monitoring Protocol (If Combination Used)
Before Prescribing
- Measure baseline serum potassium and creatinine 2
- Verify eGFR >60 mL/min 2, 4
- Review all concurrent medications for additional hyperkalemia risk 1, 2
During Treatment
- Check serum potassium at 3-5 days after starting Bactrim 2
- For courses >7 days, recheck potassium weekly 2
- Instruct patients to report muscle weakness, palpitations, or paresthesias immediately 2
If Hyperkalemia Develops (K+ >5.5 mEq/L)
- Discontinue trimethoprim-sulfamethoxazole immediately 2
- Consider temporarily holding or reducing the ACE inhibitor dose 2
- Initiate hyperkalemia management per standard protocols 2
- Switch to an alternative antibiotic 3, 6
Critical Pitfalls to Avoid
Do not assume "normal renal function" based on creatinine alone in elderly patients—calculate eGFR, as age-related muscle loss masks renal impairment 2, 5. Even mild renal insufficiency (creatinine 1.5-2.0 mg/dL) substantially increases risk 4, 5.
Do not prescribe this combination with concurrent potassium supplements or potassium-sparing diuretics—the risk of severe hyperkalemia (K+ >9 mEq/L) requiring dialysis is unacceptably high 7, 6. One case series reported potassium levels of 9.4-11 mEq/L in patients on ACE inhibitors who received amiloride, with two deaths 7.
Do not use standard-dose Bactrim without monitoring—hyperkalemia occurs with both high-dose (for PCP pneumonia) and standard-dose regimens 5. A prospective study confirmed significant potassium elevation even with standard dosing in patients with mild renal impairment 5.
Do not forget to discontinue potassium supplements when starting Bactrim in patients on ACE inhibitors—the FDA label explicitly warns about this interaction 2.
Preferred Alternative Antibiotics
When treating urinary tract infections or other common indications in patients on ACE inhibitors:
- Amoxicillin (no hyperkalemia risk) 3, 6
- Cephalexin or other cephalosporins (no hyperkalemia risk)
- Norfloxacin (minimal hyperkalemia risk, adjusted OR 1.6) 6
- Avoid nitrofurantoin (also associated with hyperkalemia, adjusted OR 2.4) 6
Special Populations
Elderly Patients (≥65 years)
The 2019 AGS Beers Criteria specifically identifies this combination as potentially inappropriate 1. The FDA label warns that elderly patients are at increased risk for severe adverse reactions, particularly hyperkalemia, when complicating conditions exist 2. In elderly patients with any renal impairment, this combination should be avoided entirely. 1, 2
Patients with Diabetes
All five patients in one case series of life-threatening hyperkalemia (K+ 9.4-11 mEq/L) from ACE inhibitor plus potassium-sparing diuretic were diabetic and over 50 years 7. Diabetes impairs potassium homeostasis and increases risk 3, 7.
Patients on Multiple RAAS Inhibitors
The 2017 ACC/AHA hypertension guideline explicitly warns against combining drugs that target the same system (e.g., ACE inhibitor + ARB + aldosterone antagonist), as this increases cardiovascular and renal risk 1. Adding trimethoprim to any RAAS inhibitor combination is particularly dangerous 1, 2.
Evidence Quality and Strength
The hyperkalemia risk is supported by:
- High-quality population-based studies showing 7-fold increased hospitalization risk 3
- FDA drug labeling with explicit warnings about this interaction 2
- Major society guidelines (AGS Beers Criteria 2019) recommending caution 1
- Mechanistic studies demonstrating trimethoprim's amiloride-like effect 4, 5
- Case series documenting life-threatening outcomes 7
This is Class I (strong recommendation), Level A (high-quality evidence) to avoid this combination in high-risk patients. 1, 2, 3